Israeli medical device firm Lumenis has launched the new Pulse 100H and Pulse 50H laser systems, which are designed to treat benign prostatic hyperplasia (BPH) and stones.

Pulse 100H, the next generation of the VersaPulse PowerSuite 100W system, is developed to treat a wide range of clinical urologic indications, including BPH, stones, tumours or strictures.

The system will also be used to treat other specialties such as general surgery, ENT, gynecology and pulmonary surgery.

It allows users to carry out holmium laser enucleation of the prostate (HoLEP), the gold standard treatment for BPH and stone dusting.

The Pulse 100H, which features dual pedals for improved ease of use and a standby mode for reducing cost per procedure, provides a combination of laser parameters addressing 70 types of procedures.

“The additions to the Pulse platform series signify a key improvement to our current urological solutions for HoLEP and stone dusting.”

The company also launched the Pulse 50H laser system that holds the capability to address any type or size of stone in lithotripsy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Pulse 50H is a comprehensive solution, which offers 0.2J of energy per pulse to minimise migration of even the smallest stone, and it can be upgraded to Pulse 100H.

Klinikum SLK Heilbronn (Germany) professor Jens Rassweiler said: “The new Pulse 50H system provides all features to perform modern intra corporeal holmium laser lithotripsy, including a wide range of energy levels and frequencies.”

The company is exhibiting these new laser systems at the 33rd World Congress of Endourology (WCE) in London, UK, which is being held from 1 – 4 October.

Lumenis CEO Tzipi Ozer-Armon said: “With our commitment to the Endourological Society, we are proud to present two new innovative systems, the Pulse 100H and 50H, to meet the developing, dynamic market need in the field of minimally invasive urological surgery.

“The additions to the Pulse platform series signify a key improvement to our current urological solutions for HoLEP and stone dusting and empower users to achieve more than 70 types of procedures in a range of clinical specialties.”

Lumenis is focused on the field of minimally invasive clinical solutions for the surgical, ophthalmology and aesthetic markets, and also develops new energy based technologies, including laser, intense pulsed light (IPL) and radio frequency (RF).

Image: The Lumenis Pulse 100H laser system. Photo: courtesy of Lumenis.